|
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
|
Phase 4 |
Recruiting |
Pfizer |
UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel |
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction
|
Phase 4 |
Recruiting |
Isala |
Netherlands |
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
NCT07744698 · ClinicalTrials.gov ↗ · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 4 |
Recruiting |
Anhui Provincial Cancer Hospital |
China |
|
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma
|
Phase 3 |
Recruiting |
National Cancer Institute (NCI) |
Norway, Mexico, Israel |
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
NCT04339218 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Cryotherapy Effect
|
Phase 3 |
Recruiting |
Institut Bergonié |
France |
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04747054 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck
|
Phase 3 |
Recruiting |
UNICANCER |
France |
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
NCT04807673 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
|
Phase 3 |
Recruiting |
Tianjin Medical University Cancer Institute and Hospital |
China |
|
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
|
Phase 3 |
Recruiting |
Hunan Province Tumor Hospital |
China |
|
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
|
Phase 3 |
Recruiting |
InSightec |
USA, Canada, South Korea |
|
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
|
Phase 3 |
Recruiting |
Gilead Sciences |
Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Brazil, Mexico, Japan, South Korea, Australia, Israel |
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
NCT05692999 · ClinicalTrials.gov ↗ · Metastatic Non-squamous Lung Cancer
|
Phase 3 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
France, Spain, Belgium |
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904 · Metastatic Melanoma, Unresectable Melanoma, Melanoma
|
Phase 3 |
Recruiting |
Iovance Biotherapeutics, Inc |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Switzerland, Canada, South Korea, Singapore, Australia, Israel |
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807 · Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8
|
Phase 3 |
Recruiting |
Alliance for Clinical Trials in Oncology |
Canada, Mexico, Israel, Egypt |
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927 · ClinicalTrials.gov ↗ · Oligometastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 3 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
Spain, Italy, Belgium, Switzerland |
|
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
|
Phase 3 |
Recruiting |
Amgen |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
|
Phase 3 |
Recruiting |
SWOG Cancer Research Network |
Mexico, Israel |
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 3 |
Recruiting |
Women's Cancer Study Group GmbH |
Germany |
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
|
Phase 3 |
Recruiting |
Beijing Tongren Hospital |
China |
|
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
|
Phase 3 |
Recruiting |
Eli Lilly and Company |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
|
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
|
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
|
Phase 3 |
Recruiting |
NovoCure GmbH |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Japan, Singapore, Israel, Egypt |
|
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
|
Phase 3 |
Recruiting |
Replimune, Inc |
UK, USA, Germany, France, Spain, Poland |
|
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
|
Phase 3 |
Recruiting |
Jazz Pharmaceuticals |
UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel |
|
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia |
|
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
CARE1 Pragmatic Clinical Trial
NCT06364631 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
|
Phase 3 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
France, Netherlands, Austria, Czechia |
|
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel |
|
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel |
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806 · ClinicalTrials.gov ↗ · Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
|
Phase 3 |
Recruiting |
National Cancer Institute (NCI) |
Canada, Mexico |
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277 · Advanced Non-small Cell Lung Cancer, HER2 Mutation
|
Phase 3 |
Recruiting |
Bayer |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482 · ClinicalTrials.gov ↗ · High-risk Melanoma
|
Phase 3 |
Recruiting |
Uppsala University |
Sweden, Norway |
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006 · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer
|
Phase 3 |
Recruiting |
Shanghai Henlius Biotech |
USA, China, Germany, Spain, Italy, Poland, Turkey, Brazil, Japan, South Korea, Australia |
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955 · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
|
Phase 3 |
Recruiting |
Ferring Pharmaceuticals |
USA, France, Spain, Denmark, Poland, Czechia, Canada, South Korea |
|
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
|
Phase 3 |
Recruiting |
Bristol-Myers Squibb |
Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730 · ClinicalTrials.gov ↗ · Breast Cancers, Triple Negative Breast Cancer (TNBC)
|
Phase 3 |
Recruiting |
UNICANCER |
France, Belgium |
|
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8
|
Phase 3 |
Recruiting |
Alliance for Clinical Trials in Oncology |
Mexico |
|
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 3 |
Recruiting |
Rakuten Medical, Inc |
USA, China, Japan, Taiwan |
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478 · Gastric Cancer, Gastroesophageal Junction Cancer
|
Phase 3 |
Recruiting |
Daiichi Sankyo |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
|
Phase 3 |
Recruiting |
Immatics US, Inc |
UK, USA, Germany, France, Netherlands, Canada, Israel |
|
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
|
Phase 3 |
Recruiting |
Qilu Pharmaceutical Co., Ltd |
China |
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
|
Phase 3 |
Recruiting |
Pfizer |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
|
Phase 3 |
Recruiting |
Summit Therapeutics |
USA, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Canada, Mexico, Japan |
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215 · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
|
Phase 3 |
Recruiting |
Hoffmann-La Roche |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Egypt |
|
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
|
Phase 3 |
Recruiting |
AstraZeneca |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel |
|
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
|
Phase 3 |
Recruiting |
Mirati Therapeutics Inc |
Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Eli Lilly and Company |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
|
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Daiichi Sankyo |
UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan |
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer
|
Phase 3 |
Recruiting |
Astellas Pharma Global Development, Inc |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
|
Phase 3 |
Recruiting |
Intergroupe Francophone de Cancerologie Thoracique |
France |
|
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
NCT06980272 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Shenyang Sunshine Pharmaceutical Co., LTD |
China |
|
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 3 |
Recruiting |
Universität des Saarlandes |
Germany, Switzerland |
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma
|
Phase 3 |
Recruiting |
National Cancer Institute (NCI) |
Mexico, Israel |
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 3 |
Recruiting |
Suzhou Suncadia Biopharmaceuticals Co., Ltd |
China |
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
NCT07178795 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Sichuan Baili Pharmaceutical Co., Ltd |
China |
|
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
|
Phase 3 |
Recruiting |
Boehringer Ingelheim |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
|
Phase 3 |
Recruiting |
National Cancer Institute (NCI) |
Mexico |
|
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
|
Phase 3 |
Recruiting |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel |
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380 · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
|
Phase 3 |
Recruiting |
Eli Lilly and Company |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
|
Phase 3 |
Recruiting |
Pfizer |
USA, India, China, Germany, France, Spain, Italy, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, Taiwan, Australia, Israel, Egypt |
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
|
Phase 3 |
Recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
France |
|
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
|
Phase 3 |
Recruiting |
Janssen Research & Development, LLC |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
|
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
|
Phase 3 |
Recruiting |
GlaxoSmithKline |
UK, Canada, Japan, South Korea, Australia |
|
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
|
Phase 3 |
Recruiting |
RemeGen Co., Ltd |
China |
|
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
|
Phase 3 |
Recruiting |
Bristol-Myers Squibb |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
NCT07362459 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Carcinoma (NSCLC)
|
Phase 3 |
Recruiting |
Sinocelltech Ltd |
China |
|
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 |
Recruiting |
Hoffmann-La Roche |
USA, China, Spain, Italy, Poland, Portugal, Canada, Brazil, Japan, South Korea |
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156 · Urothelial Cancer, Urinary Bladder Neoplasms
|
Phase 3 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA, Canada, South Korea, Taiwan |
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649 · Endometrial Neoplasms, Endometrial Cancer
|
Phase 3 |
Recruiting |
Pfizer |
USA, China, Japan, Taiwan, Australia |
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
NCT07660094 · ClinicalTrials.gov ↗ · Non-squamous, Non-Small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Candel Therapeutics, Inc |
USA |
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Phase 3 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA, China, Japan |
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 3 |
Recruiting |
Suzhou Suncadia Biopharmaceuticals Co., Ltd |
China |
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
NCT07684599 · ClinicalTrials.gov ↗ · Neoplasms, Endometrial
|
Phase 3 |
Recruiting |
GlaxoSmithKline |
Canada, Japan, South Korea |
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
NCT07710885 · ClinicalTrials.gov ↗ · Biliary Tract Cancer
|
Phase 3 |
Recruiting |
Taiho Pharmaceutical Co., Ltd |
Japan, South Korea, Australia |
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma
|
Phase 3 |
Recruiting |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
|
Phase 3 |
Recruiting |
Exelixis |
USA |
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
NCT07756645 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 3 |
Recruiting |
AbbVie |
USA |
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822 · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC
|
Phase 3 |
Recruiting |
Revolution Medicines, Inc |
USA |
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
NCT07802821 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer
|
Phase 3 |
Recruiting |
Qilu Pharmaceutical Co., Ltd |
China |
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
|
Phase 2/3 |
Recruiting |
Mirati Therapeutics Inc |
Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel, Egypt |
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
NCT05595447 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
|
Phase 2/3 |
Recruiting |
Hospital Regional de Alta Especialidad del Bajio |
Mexico |
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731 · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
|
Phase 2/3 |
Recruiting |
Inhibrx Biosciences, Inc |
UK, USA, China, France, Spain, Italy, Belgium, Poland, South Korea, Taiwan, Australia |
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
NCT06493552 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
|
Phase 2/3 |
Recruiting |
Vasgene Therapeutics, Inc |
USA |
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
|
Phase 2/3 |
Recruiting |
Linnaeus Therapeutics, Inc |
USA, Mexico |
|
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
|
Phase 2/3 |
Recruiting |
Eikon Therapeutics |
UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, South Korea, Australia, Israel |
|
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
|
Phase 2/3 |
Recruiting |
BioNTech SE |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Turkey, Brazil, Japan, South Korea, Australia |
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 2/3 |
Recruiting |
Bicara Therapeutics |
Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
NCT06923475 · ClinicalTrials.gov ↗ · Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma
|
Phase 2/3 |
Recruiting |
Amsterdam UMC, location VUmc |
Netherlands |
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928 · Advanced Or Metastatic Merkel Cell Carcinoma
|
Phase 2/3 |
Recruiting |
TuHURA Biosciences, Inc |
USA |
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion
|
Phase 2/3 |
Recruiting |
Bristol-Myers Squibb |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
|
Phase 2/3 |
Recruiting |
Eikon Therapeutics |
USA, Germany, Spain, Belgium, Poland, Austria, Brazil, Mexico, South Korea, Australia |
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07815665 · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
|
Phase 2/3 |
Recruiting |
Summit Therapeutics |
USA |
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasm
|
Phase 2 |
Recruiting |
The Netherlands Cancer Institute |
Netherlands |
Melanoma Metastasized to the Brain and Steroids
NCT03563729 · ClinicalTrials.gov ↗ · Malignant Melanoma
|
Phase 2 |
Recruiting |
Inge Marie Svane |
Denmark |
|
Pan Tumor Rollover Study
|
Phase 2 |
Recruiting |
Bristol-Myers Squibb |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
NCT03971045 · ClinicalTrials.gov ↗ · Breast Cancer, Chest Wall Tumor
|
Phase 2 |
Recruiting |
European Institute of Oncology |
Italy |
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
NCT04109755 · ClinicalTrials.gov ↗ · Rectum Cancer, Rectal Cancer
|
Phase 2 |
Recruiting |
University Hospital, Geneva |
Switzerland |
Sacituzumab Govitecan In TNBC
NCT04230109 · ClinicalTrials.gov ↗ · Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer
|
Phase 2 |
Recruiting |
Massachusetts General Hospital |
Israel |
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
NCT04510636 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
|
Phase 2 |
Recruiting |
University Health Network, Toronto |
Canada |
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
NCT04519151 · Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach
|
Phase 2 |
Recruiting |
Sheba Medical Center |
Israel |
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
NCT04602377 · ClinicalTrials.gov ↗ · Small Cell Ovarian Carcinoma
|
Phase 2 |
Recruiting |
ARCAGY/ GINECO GROUP |
France |
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
National Cancer Institute (NCI) |
Mexico |
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
NCT04838652 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma
|
Phase 2 |
Recruiting |
University of Cologne |
Germany |
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
NCT04857164 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
Yuankai Shi |
China |
|
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
|
Phase 2 |
Recruiting |
Seagen, a wholly owned subsidiary of Pfizer |
UK, USA, Spain, Italy, Belgium, Turkey, Canada, Japan, Australia, Israel |
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
|
Phase 2 |
Recruiting |
ImmunoVaccine Technologies, Inc. (IMV Inc.) |
USA, France, Spain, Poland, Canada, Australia |
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
NCT05025813 · ClinicalTrials.gov ↗ · Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
|
Phase 2 |
Recruiting |
Queensland Health |
Australia |
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Neoplasms, Bladder Tumors
|
Phase 2 |
Recruiting |
Peking University First Hospital |
China |
|
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
|
Phase 2 |
Recruiting |
Canadian Cancer Trials Group |
Canada, Australia |
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846 · ClinicalTrials.gov ↗ · ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy
|
Phase 2 |
Recruiting |
Hunan Province Tumor Hospital |
China |
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
NCT05284539 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2 |
Recruiting |
Hunan Province Tumor Hospital |
China |
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
|
Phase 2 |
Recruiting |
NRG Oncology |
Ireland, Canada, Mexico, Australia, Israel |
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer
|
Phase 2 |
Recruiting |
Rutgers, The State University of New Jersey |
Israel |
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
NCT05485766 · Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms
|
Phase 2 |
Recruiting |
Okayama University |
Japan |
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NCT05725200 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
|
Phase 2 |
Recruiting |
Oslo University Hospital |
Norway |
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
NCT05832827 · ClinicalTrials.gov ↗ · Untreated Advanced or Recurrent Thymic Carcinomas
|
Phase 2 |
Recruiting |
National Cancer Center, Japan |
Japan |
Pembrolizumab in High-risk Thyroid Cancer
NCT05852223 · ClinicalTrials.gov ↗ · Differentiated Thyroid Cancer
|
Phase 2 |
Recruiting |
Istituti Clinici Scientifici Maugeri SpA |
Italy |
|
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
|
Phase 2 |
Recruiting |
Kyoto University Hospital |
Japan |
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05903833 · ClinicalTrials.gov ↗ · Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer
|
Phase 2 |
Recruiting |
AGO Research GmbH |
Germany |
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
NCT05925491 · ClinicalTrials.gov ↗ · Sinonasal Undifferentiated Carcinoma
|
Phase 2 |
Recruiting |
Istituti Clinici Scientifici Maugeri SpA |
Italy |
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
NCT05961761 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma
|
Phase 2 |
Recruiting |
Niels Junker |
Sweden, Denmark, Norway |
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms
|
Phase 2 |
Recruiting |
UNICANCER |
France |
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
NCT05980702 · ClinicalTrials.gov ↗ · HNSCC, Oral Cancer, PD-1
|
Phase 2 |
Recruiting |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China |
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer
|
Phase 2 |
Recruiting |
UNICANCER |
France, Spain |
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
NCT06100497 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
Beijing Tongren Hospital |
China |
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
NCT06137378 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III
|
Phase 2 |
Recruiting |
University of Leipzig |
Germany |
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151 · ClinicalTrials.gov ↗ · Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
|
Phase 2 |
Recruiting |
Precigen, Inc |
USA |
|
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
|
Phase 2 |
Recruiting |
Philogen S.p.A |
USA, Germany, Italy |
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
NCT06302569 · ClinicalTrials.gov ↗ · Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma
|
Phase 2 |
Recruiting |
Giuseppe Procopio |
Italy |
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
NCT06353906 · ClinicalTrials.gov ↗ · Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases
|
Phase 2 |
Recruiting |
The Netherlands Cancer Institute |
Netherlands, Belgium |
ALPINE: Maintenance Letrozole/Abemaciclib
NCT06366347 · ClinicalTrials.gov ↗ · Endometrial Cancer, Recurrent Endometrial Cancer, TP53
|
Phase 2 |
Recruiting |
Dana-Farber Cancer Institute |
Israel |
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab
|
Phase 2 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
China |
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
NCT06482801 · ClinicalTrials.gov ↗ · Liver Cancer, Antibody
|
Phase 2 |
Recruiting |
Second Affiliated Hospital of Guangzhou Medical University |
China |
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT06483347 · ClinicalTrials.gov ↗ · Lung Cancer, Inoperable Disease
|
Phase 2 |
Recruiting |
Second Affiliated Hospital of Guangzhou Medical University |
China |
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
NCT06484153 · ClinicalTrials.gov ↗ · To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
|
Phase 2 |
Recruiting |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
China |
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
NCT06502743 · ClinicalTrials.gov ↗ · Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma
|
Phase 2 |
Recruiting |
Yonsei University |
South Korea |
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
NCT06640283 · ClinicalTrials.gov ↗ · HPV-Related Carcinoma, Uterine Cervical Cancer, Anal Canal Cancer
|
Phase 2 |
Recruiting |
Instituto do Cancer do Estado de São Paulo |
Brazil |
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
NCT06651151 · ClinicalTrials.gov ↗ · Melanoma Stage IIIB-IV
|
Phase 2 |
Recruiting |
Oslo University Hospital |
Norway |
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
NCT06667167 · ClinicalTrials.gov ↗ · NSCLC (non-small Cell Lung Cancer)
|
Phase 2 |
Recruiting |
Nir Peled |
Israel |
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
NCT06670911 · ClinicalTrials.gov ↗ · Persistent, Recurrent, or Metastatic Cervical Cancer
|
Phase 2 |
Recruiting |
Instituto Nacional de Cancer, Brazil |
Brazil |
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
NCT06673628 · ClinicalTrials.gov ↗ · Angiosarcoma of Skin, Angiosarcoma Metastatic
|
Phase 2 |
Recruiting |
National Cancer Center, Japan |
Japan |
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
NCT06708858 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer
|
Phase 2 |
Recruiting |
Dai, Guanghai |
China |
|
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Spain, Italy, Poland, Turkey, Taiwan, Israel |
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
|
Phase 2 |
Recruiting |
National Cancer Institute (NCI) |
Canada |
|
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Spain, South Korea, Taiwan |
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
NCT06822543 · ClinicalTrials.gov ↗ · Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases
|
Phase 2 |
Recruiting |
Latin American Cooperative Oncology Group |
Brazil |
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
NCT06846268 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer
|
Phase 2 |
Recruiting |
National University Hospital, Singapore |
Singapore |
Probiotics in Advanced Urothelial Carcinoma
NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
|
Phase 2 |
Recruiting |
Sun Yat-sen University |
China |
|
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Germany, France, Spain, Italy, Poland, Portugal, Canada, Australia, Israel |
|
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
|
Phase 2 |
Recruiting |
Sichuan Baili Pharmaceutical Co., Ltd |
China |
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
NCT06976944 · ClinicalTrials.gov ↗ · Recurrent Triple-Negative Breast Cancer
|
Phase 2 |
Recruiting |
Yukinori Ozaki |
Japan |
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
NCT06978114 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer
|
Phase 2 |
Recruiting |
Sichuan Baili Pharmaceutical Co., Ltd |
China |
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
NCT06999980 · ClinicalTrials.gov ↗ · Cutaneous Melanoma, Mucosal Melanoma
|
Phase 2 |
Recruiting |
Melanoma Institute Australia |
Australia |
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
NCT07018570 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Phase 2 |
Recruiting |
National Cancer Center Hospital East |
Japan |
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
NCT07054567 · ClinicalTrials.gov ↗ · Cervical Cancer, Endometrial Cancer
|
Phase 2 |
Recruiting |
Sichuan Baili Pharmaceutical Co., Ltd |
China |
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
NCT07098988 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
|
Phase 2 |
Recruiting |
CatalYm GmbH |
USA, Germany, Spain, Italy, Poland, Switzerland |
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
|
Phase 2 |
Recruiting |
Peking Union Medical College Hospital |
China |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
NCT07176312 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer
|
Phase 2 |
Recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Germany |
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
NCT07188246 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
|
Phase 2 |
Recruiting |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
Canada |
|
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, France, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia |
|
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Spain, Italy, Netherlands, Turkey, South Korea |
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
NCT07254585 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
CSPC Megalith Biopharmaceutical Co.,Ltd |
China |
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
NCT07264816 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer
|
Phase 2 |
Recruiting |
Sichuan Baili Pharmaceutical Co., Ltd |
China |
|
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
|
Phase 2 |
Recruiting |
National Cancer Institute, Naples |
Italy |
Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
NCT07349303 · ClinicalTrials.gov ↗ · Melanoma (Skin Cancer)
|
Phase 2 |
Recruiting |
Vastra Gotaland Region |
Sweden |
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
NCT07360743 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous)
|
Phase 2 |
Recruiting |
UNICANCER |
France |
|
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
|
Phase 2 |
Recruiting |
Mirati Therapeutics Inc |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Singapore, Australia, Israel |
A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
NCT07448831 · ClinicalTrials.gov ↗ · Melanoma (Skin Cancer)
|
Phase 2 |
Recruiting |
Universitair Ziekenhuis Brussel |
Belgium |
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT07452224 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 |
Recruiting |
iLeukon Therapeutics, Inc |
USA |
|
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
|
Phase 2 |
Recruiting |
Astellas Pharma Global Development, Inc |
UK, USA, China, Germany, France, Spain, Italy, Poland, Canada, Japan, South Korea, Australia |
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell
|
Phase 2 |
Recruiting |
Boehringer Ingelheim |
China, Germany, France, Spain, Japan, South Korea, Australia |
|
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
|
Phase 2 |
Recruiting |
Primmune Therapeutics, Inc |
Australia |
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer
|
Phase 2 |
Recruiting |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
China |
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 2 |
Recruiting |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd |
China |
|
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
|
Phase 2 |
Recruiting |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd |
China |
|
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
AbbVie |
USA, China, Japan, Taiwan |
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors
|
Phase 2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Switzerland, Canada |
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Recruiting |
Bicara Therapeutics |
USA |
|
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
|
Phase 2 |
Recruiting |
Solstice Oncology, Inc |
UK, USA, Spain, Italy, Netherlands, Belgium |
|
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
|
Phase 2 |
Recruiting |
Vividion Therapeutics, Inc |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Singapore |
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
NCT07850791 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)
|
Phase 2 |
Recruiting |
Haitao Zhao, MD |
China |
|
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Italy, Sweden, Portugal, Brazil, South Korea, Israel |
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
NCT04014530 · ClinicalTrials.gov ↗ · Colorectal Cancer, Endometrium Cancer
|
Phase 1/2 |
Recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands |
|
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel |
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
|
Phase 1/2 |
Recruiting |
Inhibrx Biosciences, Inc |
USA, South Korea, Taiwan, Singapore |
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT04421560 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer
|
Phase 1/2 |
Recruiting |
Dana-Farber Cancer Institute |
Israel |
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 · Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer
|
Phase 1/2 |
Recruiting |
PMV Pharmaceuticals, Inc |
UK, USA, Germany, France, Spain, Italy, South Korea, Singapore, Australia |
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
NCT04592211 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV
|
Phase 1/2 |
Recruiting |
Yonsei University |
South Korea |
|
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
|
Phase 1/2 |
Recruiting |
Simcha IL-18, Inc |
USA |
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific
|
Phase 1/2 |
Recruiting |
Maastricht University Medical Center |
Spain, Netherlands, Belgium |
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453 · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer
|
Phase 1/2 |
Recruiting |
GI Innovation, Inc |
USA, South Korea |
|
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
|
Phase 1/2 |
Recruiting |
Shionogi |
USA, Japan |
|
First in Human Study of T3P-Y058-739 (T3P)
|
Phase 1/2 |
Recruiting |
T3 Pharmaceuticals AG |
UK, Spain, Switzerland |
RAPA-201 Therapy of Solid Tumors
NCT05144698 · Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer
|
Phase 1/2 |
Recruiting |
Rapa Therapeutics LLC |
USA |
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338 · ClinicalTrials.gov ↗ · Lung Cancer, Liver Cancer, Colorectal Cancer
|
Phase 1/2 |
Recruiting |
Second Affiliated Hospital of Guangzhou Medical University |
China |
|
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Germany, Italy, Switzerland, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore |
A Study in Patients With Advanced Cancers
NCT05320588 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Solid Tumor, Cancer
|
Phase 1/2 |
Recruiting |
BiOneCure Therapeutics Inc |
USA |
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532 · Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma
|
Phase 1/2 |
Recruiting |
Scancell Ltd |
UK |
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT05356741 · Locally Advanced or Metastatic HER2-Expressing Cancers
|
Phase 1/2 |
Recruiting |
Vir Biotechnology, Inc |
USA, France, Spain, Portugal, Australia |
|
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
Qurient Co., Ltd |
USA, South Korea |
|
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/2 |
Recruiting |
Adagene Inc |
USA, China, South Korea |
|
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
|
Phase 1/2 |
Recruiting |
D3 Bio (Wuxi) Co., Ltd |
USA, China, Germany, France, Spain, Italy, Japan, South Korea, Australia |
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
|
Phase 1/2 |
Recruiting |
Phanes Therapeutics |
USA |
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
NCT05438459 · ClinicalTrials.gov ↗ · Gastric Cancer, Pancreatic Cancer
|
Phase 1/2 |
Recruiting |
Kyushu University |
Japan |
|
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
|
Phase 1/2 |
Recruiting |
Tvardi Therapeutics, Incorporated |
USA |
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
|
Phase 1/2 |
Recruiting |
Phanes Therapeutics |
USA |
|
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
ModernaTX, Inc |
UK, USA, Germany, Spain, Italy, Poland, Australia |
|
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, Spain, Italy, Netherlands, Denmark, Canada, South Korea, Australia, Israel |
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366 · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma
|
Phase 1/2 |
Recruiting |
Genmab |
USA, China, Japan, South Korea |
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 · Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC)
|
Phase 1/2 |
Recruiting |
GV20 Therapeutics |
USA |
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor
|
Phase 1/2 |
Recruiting |
Tango Therapeutics, Inc |
USA, France, Spain |
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 |
Recruiting |
1ST Biotherapeutics, Inc |
USA |
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688 · Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma
|
Phase 1/2 |
Recruiting |
TiumBio Co., Ltd |
USA, South Korea |
|
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
|
Phase 1/2 |
Recruiting |
Hoffmann-La Roche |
UK, USA, China, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168 · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer
|
Phase 1/2 |
Recruiting |
AstraZeneca |
UK, USA, China, Germany, Spain, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel |
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
|
Phase 1/2 |
Recruiting |
GI Innovation, Inc |
USA, South Korea |
|
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
|
Phase 1/2 |
Recruiting |
CJ Bioscience, Inc |
USA, South Korea |
|
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
|
Phase 1/2 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
China |
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497 · Cancer, Melanoma Stage III, Melanoma Stage IV
|
Phase 1/2 |
Recruiting |
Krystal Biotech, Inc |
USA |
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
NCT05978102 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 |
Recruiting |
The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
China |
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
NCT06016920 · HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
|
Phase 1/2 |
Recruiting |
Nykode Therapeutics ASA |
UK, Germany, France, Spain, Poland, Norway |
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult
|
Phase 1/2 |
Recruiting |
Neonc Technologies, Inc |
USA |
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144 · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
|
Phase 1/2 |
Recruiting |
AstraZeneca |
UK, USA, China, Germany, France, Spain, Italy, Brazil, Japan, South Korea, Australia |
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
|
Phase 1/2 |
Recruiting |
Revolution Medicines, Inc |
USA, Germany, France, Spain, Italy, Netherlands, Denmark, Austria, Czechia, South Korea, Taiwan, Australia |
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult
|
Phase 1/2 |
Recruiting |
Krystal Biotech, Inc |
USA |
|
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
|
Phase 1/2 |
Recruiting |
Strand Therapeutics Inc |
USA, Australia |
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
NCT06293651 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
|
Phase 1/2 |
Recruiting |
Dong-A ST Co., Ltd |
South Korea |
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
NCT06384560 · ClinicalTrials.gov ↗ · Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
|
Phase 1/2 |
Recruiting |
Amsterdam UMC, location VUmc |
Netherlands |
|
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
|
Phase 1/2 |
Recruiting |
Janssen Research & Development, LLC |
UK, USA, China, Germany, France, Spain, Poland, Japan, South Korea, Taiwan |
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia |
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan |
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
NCT06530303 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colon Cancer, Rectum Cancer
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799 · ClinicalTrials.gov ↗ · Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
|
Ixovex-1 Single Agent and Combination Therapy
|
Phase 1/2 |
Recruiting |
Psivac Ltd |
UK |
|
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
Bristol-Myers Squibb |
UK, USA, France, Spain, Italy, Netherlands, Canada, Taiwan, Australia |
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06640582 · ClinicalTrials.gov ↗ · Brain Tumor, Brain Metastases, Brain Cancer
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585 · Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
|
Phase 1/2 |
Recruiting |
Alentis Therapeutics AG |
USA, France, Spain, Italy, South Korea, Taiwan, Singapore |
|
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
|
Phase 1/2 |
Recruiting |
AbbVie |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Japan, Taiwan, Australia |
|
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore |
|
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
Pyxis Oncology, Inc |
USA, France, Spain |
|
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, Spain, Switzerland, Canada, South Korea, Taiwan, Australia, Israel |
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
NCT06877650 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors
|
Phase 1/2 |
Recruiting |
Shanghai JMT-Bio Inc |
China |
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
NCT06911827 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 |
Recruiting |
Qilu Pharmaceutical Co., Ltd |
China |
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT06942234 · ClinicalTrials.gov ↗ · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
|
Phase 1/2 |
Recruiting |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
China |
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer
|
Phase 1/2 |
Recruiting |
Verastem, Inc |
USA, France, Spain, Australia |
|
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
|
Phase 1/2 |
Recruiting |
Taipei Veterans General Hospital, Taiwan |
Taiwan |
|
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
|
Phase 1/2 |
Recruiting |
ABL Bio, Inc |
USA, South Korea, Australia |
|
A Study of YL242 in Subjects With Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
MediLink Therapeutics (Suzhou) Co., Ltd |
USA, China, Australia |
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047 · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
|
Phase 1/2 |
Recruiting |
Bristol-Myers Squibb |
USA, Spain, Canada |
|
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
UK, USA, France, Spain, Netherlands, South Korea, Israel |
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
NCT07255664 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced
|
Phase 1/2 |
Recruiting |
CuraCell TX AB |
Germany |
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 |
Recruiting |
Qilu Pharmaceutical Co., Ltd |
China |
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619 · Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer
|
Phase 1/2 |
Recruiting |
Eikon Therapeutics |
USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Norway, Portugal, South Korea, Singapore, Australia |
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917 · Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
|
Phase 1/2 |
Recruiting |
Aminex Therapeutics, Inc |
USA |
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995 · Locally Advanced or Metastatic Malignant Solid Tumors
|
Phase 1/2 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA, Japan |
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
NCT07302347 · ClinicalTrials.gov ↗ · Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
|
Phase 1/2 |
Recruiting |
Merck Sharp & Dohme LLC |
Japan |
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT07410676 · ClinicalTrials.gov ↗ · Cancer, Sarcoma, Leukaemia
|
Phase 1/2 |
Recruiting |
Essen Biotech |
China |
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
NCT07639450 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
|
Phase 1/2 |
Recruiting |
Hefei Xinzhu Biological Technology Co., Ltd |
China, Australia |
|
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
|
Phase 1/2 |
Recruiting |
PharmaMar |
USA, Spain |
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
NCT07730021 · Locally Advanced or Metastatic Solid Tumors
|
Phase 1/2 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA, Japan |
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966 · ClinicalTrials.gov ↗ · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
|
Phase 1/2 |
Recruiting |
Daiichi Sankyo |
USA, China, France, Spain, Italy, Belgium, Austria, Turkey, Brazil, Japan, Taiwan |
|
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
|
Phase 1/2 |
Recruiting |
Arvinas Inc |
USA |
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
NCT07890714 · ClinicalTrials.gov ↗ · Urothelial Cancer, Non-small Cell Lung Cancer
|
Phase 1/2 |
Recruiting |
Daiichi Sankyo |
Taiwan |
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms
|
Phase 1 |
Recruiting |
Seagen, a wholly owned subsidiary of Pfizer |
UK, USA, France, Spain, Switzerland, South Korea, Taiwan, Israel |
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542 · Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer
|
Phase 1 |
Recruiting |
Bicara Therapeutics |
USA, Canada, Australia |
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT04991948 · Unresectable Metastatic Colorectal Cancer
|
Phase 1 |
Recruiting |
Celyad Oncology SA |
USA, Belgium |
|
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
|
Phase 1 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel |
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
NCT05205109 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Antengene Therapeutics Limited |
China, Australia |
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma
|
Phase 1 |
Recruiting |
Seagen, a wholly owned subsidiary of Pfizer |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Japan |
|
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Riboscience, LLC |
USA |
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
|
Phase 1 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA, China, France, Spain, Italy, Japan, South Korea |
|
A Study of ASP3082 in Adults With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
Astellas Pharma Inc |
USA, China, France, Spain, Japan, South Korea, Israel |
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT05492682 · ClinicalTrials.gov ↗ · Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer
|
Phase 1 |
Recruiting |
Valo Therapeutics Oy |
Germany, Italy |
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
NCT05547321 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1 |
Recruiting |
Oncomatryx Biopharma S.L |
USA, Spain, Israel |
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
|
Phase 1 |
Recruiting |
Eli Lilly and Company |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Norway, Canada, Japan, South Korea, Australia, Israel |
A Study of EBC-129 in Advanced Solid Tumours
NCT05701527 · ClinicalTrials.gov ↗ · Advanced Solid Tumours
|
Phase 1 |
Recruiting |
EDDC (Experimental Drug Development Centre), A*STAR Research Entities |
Taiwan, Singapore |
|
A Study of ASP1002 in Adults for Treatment of Solid Tumors
|
Phase 1 |
Recruiting |
Astellas Pharma Global Development, Inc |
USA |
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
NCT05785754 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
DynamiCure Biotechnology |
USA, South Korea, Taiwan, Australia |
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981 · Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer
|
Phase 1 |
Recruiting |
Sairopa B.V |
USA, Spain, Belgium |
|
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
|
Phase 1 |
Recruiting |
Chugai Pharmaceutical |
USA, Japan |
|
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
Vividion Therapeutics, Inc |
USA, Spain, South Korea |
|
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
|
Phase 1 |
Recruiting |
PharmAbcine |
Australia |
|
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
Vividion Therapeutics, Inc |
UK, USA, China, France, Spain, Belgium, Denmark, Canada, South Korea, Australia |
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050 · Advanced Solid Tumor, Metastatic Solid Tumor
|
Phase 1 |
Recruiting |
Jazz Pharmaceuticals |
USA |
|
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Hanmi Pharmaceutical Company Limited |
USA, South Korea |
|
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Pliant Therapeutics, Inc |
USA, Spain |
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402 · Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC
|
Phase 1 |
Recruiting |
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) |
USA, Spain, Denmark, Canada, Australia |
|
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
MediLink Therapeutics (Suzhou) Co., Ltd |
USA, China, Canada, Japan, Australia |
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472 · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms
|
Phase 1 |
Recruiting |
Eli Lilly and Company |
USA, France, Spain, Italy, Japan, South Korea, Australia |
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
NCT06415487 · Locally Advanced Solid Tumor, Metastatic Solid Tumor
|
Phase 1 |
Recruiting |
Acepodia Biotech, Inc |
USA, Taiwan |
|
First In Human Study of CX-801 in Advanced Solid Tumors
|
Phase 1 |
Recruiting |
CytomX Therapeutics |
USA |
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 · Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor
|
Phase 1 |
Recruiting |
Eli Lilly and Company |
UK, USA, China, France, Spain, Japan, South Korea, Australia |
|
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Teva Branded Pharmaceutical Products R&D LLC |
USA, Canada |
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
NCT06513624 · ClinicalTrials.gov ↗ · With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
|
Phase 1 |
Recruiting |
National University Hospital, Singapore |
Singapore |
Study of XB010 in Subjects With Solid Tumors
NCT06545331 · Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer
|
Phase 1 |
Recruiting |
Exelixis |
UK, USA |
|
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
|
Phase 1 |
Recruiting |
GlaxoSmithKline |
UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Israel |
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer
|
Phase 1 |
Recruiting |
Eli Lilly and Company |
USA, Germany, France, Spain, Japan, South Korea |
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
|
Phase 1 |
Recruiting |
Alnylam Pharmaceuticals |
USA, Italy, South Korea |
|
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Hanmi Pharmaceutical Company Limited |
USA, South Korea |
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
NCT06736379 · ClinicalTrials.gov ↗ · Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors
|
Phase 1 |
Recruiting |
VLP Therapeutics |
USA |
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569 · Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer)
|
Phase 1 |
Recruiting |
Alterome Therapeutics, Inc |
USA |
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer
|
Phase 1 |
Recruiting |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
China |
|
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
|
Phase 1 |
Recruiting |
ModernaTX, Inc |
USA |
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079 · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma
|
Phase 1 |
Recruiting |
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) |
USA, Australia |
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06940440 · Advanced Or Metastatic Merkel Cell Carcinoma
|
Phase 1 |
Recruiting |
TuHURA Biosciences, Inc |
USA |
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06960395 · ClinicalTrials.gov ↗ · Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
|
Phase 1 |
Recruiting |
Vir Biotechnology, Inc |
USA, Australia |
|
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
HC Biopharma Inc |
China |
|
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Erasca, Inc |
USA, Canada, South Korea |
|
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
|
Phase 1 |
Recruiting |
Kumquat Biosciences Inc |
USA |
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
NCT07016997 · ClinicalTrials.gov ↗ · Solid Tumors, Refractory Cancer
|
Phase 1 |
Recruiting |
Chiome Bioscience Inc |
Japan |
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms
|
Phase 1 |
Recruiting |
Eli Lilly and Company |
USA, China, France, Spain, Japan, South Korea |
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113 · KRAS Altered Advanced or Metastatic Solid Tumors
|
Phase 1 |
Recruiting |
Amgen |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, South Korea, Australia |
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT07123415 · ClinicalTrials.gov ↗ · Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
|
Phase 1 |
Recruiting |
Aptabio Therapeutics, Inc |
South Korea |
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
NCT07128303 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1 |
Recruiting |
Gilead Sciences |
USA, Spain, South Korea, Israel |
|
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
|
Phase 1 |
Recruiting |
EMD Serono Research & Development Institute, Inc |
USA, Canada, Japan |
|
A Study of DS5361b in Participants With Advanced Solid Tumors
|
Phase 1 |
Recruiting |
Daiichi Sankyo |
USA, Japan |
|
TLN-372 in Advanced KRAS Mutant Solid Tumors
|
Phase 1 |
Recruiting |
Treeline Biosciences, Inc |
USA, Spain, Canada, Australia |
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168 · Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer
|
Phase 1 |
Recruiting |
Sutro Biopharma, Inc |
USA |
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
NCT07231458 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1 |
Recruiting |
Abalos Therapeutics GmbH |
Germany, Spain |
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
NCT07244393 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer (mCRPC)
|
Phase 1 |
Recruiting |
Cellbion Co., Ltd |
South Korea |
|
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
|
Phase 1 |
Recruiting |
Merck Sharp & Dohme LLC |
USA, Spain, Canada, South Korea, Australia, Israel |
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022 · Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
|
Phase 1 |
Recruiting |
Generate Biomedicines |
USA |
|
Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies
|
Phase 1 |
Recruiting |
Mestag Therapeutics Limited |
Spain |
|
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
|
Phase 1 |
Recruiting |
Immunomic Therapeutics, Inc |
USA |
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345 · Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
|
Phase 1 |
Recruiting |
Sutro Biopharma, Inc |
USA |
International Multicentric Study ARON-1
NCT05287464 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma (mRCC)
|
Observational |
Recruiting |
Hospital of Macerata |
Italy |
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
NCT05916755 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Observational |
Recruiting |
Vall d'Hebron Institute of Oncology |
Spain |
|
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
|
Observational |
Recruiting |
CHA University |
South Korea |
The Immune Assessment of PD-1 Antibody Therapy in Tumor
NCT06693440 · ClinicalTrials.gov ↗ · Efficacy, Team, Adverse Event
|
Observational |
Recruiting |
Quanli Gao |
China |
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
NCT07092670 · ClinicalTrials.gov ↗ · Melanoma, Fertility
|
Observational |
Recruiting |
Intergruppo Melanoma Italiano |
Italy |
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
NCT07394062 · ClinicalTrials.gov ↗ · Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer
|
Observational |
Recruiting |
Gazi University |
Turkey |
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT07419932 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Neoplasms
|
Observational |
Recruiting |
Fujian Medical University |
China |
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
NCT03769129 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Not applicable |
Recruiting |
Second Affiliated Hospital of Guangzhou Medical University |
China |
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
NCT05047094 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
|
Not applicable |
Recruiting |
Alpha Tau Medical LTD |
Israel |
|
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
|
Phase 4 |
Not yet open |
Fujian Medical University |
China |
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730 · ClinicalTrials.gov ↗ · Breast Cancer, Triple-negative Breast Cancer
|
Phase 3 |
Not yet open |
Women's Cancer Study Group GmbH |
Germany |
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
NCT07715396 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Metastatic
|
Phase 3 |
Not yet open |
AIO-Studien-gGmbH |
Germany |
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
NCT06276504 · ClinicalTrials.gov ↗ · Progressive Multifocal Leukoencephalopathy
|
Phase 2/3 |
Not yet open |
Assistance Publique - Hôpitaux de Paris |
France |
|
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
|
Phase 2/3 |
Not yet open |
Shanghai Henlius Biotech |
China |
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
NCT05386056 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
|
Phase 2 |
Not yet open |
Peking University |
China |
|
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
|
Phase 2 |
Not yet open |
Oncotelic Inc |
USA |
|
Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
|
Phase 2 |
Not yet open |
Zealand University Hospital |
Denmark |
|
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
|
Phase 2 |
Not yet open |
University of Cologne |
Germany |
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
NCT06371807 · ClinicalTrials.gov ↗ · Early Breast Cancer, Triple Negative Breast Cancer
|
Phase 2 |
Not yet open |
Fundacao Champalimaud |
Portugal |
|
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.
|
Phase 2 |
Not yet open |
GERCOR - Multidisciplinary Oncology Cooperative Group |
France |
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
NCT06805864 · ClinicalTrials.gov ↗ · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
|
Phase 2 |
Not yet open |
Gunma University |
Japan |
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06814067 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
|
Phase 2 |
Not yet open |
Fudan University |
China |
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
NCT06951399 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma
|
Phase 2 |
Not yet open |
Rabin Medical Center |
Israel |
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
NCT07054242 · ClinicalTrials.gov ↗ · Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
|
Phase 2 |
Not yet open |
Yantai Yuhuangding Hospital |
China |
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib
|
Phase 2 |
Not yet open |
Peking Union Medical College Hospital |
China |
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
NCT07347210 · ClinicalTrials.gov ↗ · Primary Glioblastoma
|
Phase 2 |
Not yet open |
Centre Hospitalier Universitaire de Besancon |
France |
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)
|
Phase 2 |
Not yet open |
Intergroupe Francophone de Cancerologie Thoracique |
France |
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
NCT07466927 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer
|
Phase 2 |
Not yet open |
Fudan University |
China |
|
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
|
Phase 2 |
Not yet open |
The Netherlands Cancer Institute |
Netherlands |
|
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)
|
Phase 2 |
Not yet open |
Vall d'Hebron Institute of Oncology |
Spain |
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
NCT07840001 · ClinicalTrials.gov ↗ · Locally Advanced Clear Cell Renal Cell Carcinoma
|
Phase 2 |
Not yet open |
Peter MacCallum Cancer Centre, Australia |
Australia |
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
NCT07840456 · ClinicalTrials.gov ↗ · Carcinoma, Squamous Cell of Head and Neck HNSCC
|
Phase 2 |
Not yet open |
University Hospital, Basel, Switzerland |
Germany, Switzerland |
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
NCT07269158 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
|
Phase 1/2 |
Not yet open |
Yonsei University |
South Korea |
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
NCT07632235 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)
|
Phase 1/2 |
Not yet open |
Shanghai 6th People's Hospital |
China |
|
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
|
Phase 1/2 |
Not yet open |
BreakBio Corp |
USA |
|
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
|
Phase 1/2 |
Not yet open |
BreakBio Corp |
USA |
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07217496 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
|
Phase 1 |
Not yet open |
ImmunityBio, Inc |
USA |
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
NCT07910942 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 1 |
Not yet open |
Kanvas Biosciences |
USA, Canada |
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003 · Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer
|
Phase 1 |
By invitation |
Rondo Therapeutics |
USA |
Development and Analysis of a Stool Bank for Cancer Patients
NCT04291755 · Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
|
Observational |
By invitation |
Persephone Biosciences |
USA |
|
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
|
Not applicable |
By invitation |
China Medical University Hospital |
China, Taiwan |
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic
|
Phase 4 |
Active, closed |
Nikolaj Frost MD |
Germany |
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Ireland, Canada, Mexico, Israel |
|
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
|
Phase 3 |
Active, closed |
Eisai Inc |
Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Japan, South Korea, Australia, Israel |
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874 · ClinicalTrials.gov ↗ · Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Norway, Canada, Mexico, Israel, Egypt |
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384 · ClinicalTrials.gov ↗ · Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Norway, Egypt |
|
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
|
Phase 3 |
Active, closed |
Janssen Research & Development, LLC |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt |
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Canada, Brazil, Japan, Australia, Israel |
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032 · High-risk Non-muscle Invasive Bladder Cancer
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt |
|
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, Germany, France, Spain, Belgium, Poland, Switzerland, Austria, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
|
Phase 3 |
Active, closed |
Hoffmann-La Roche |
USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel |
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
|
Phase 3 |
Active, closed |
UNICANCER |
France |
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179 · ClinicalTrials.gov ↗ · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Canada, Mexico, Israel |
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612 · ClinicalTrials.gov ↗ · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Canada, Mexico, Japan, South Korea, Israel, Egypt |
|
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Turkey, Canada, Mexico, Japan, South Korea, Singapore, Australia, Israel |
|
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Eli Lilly and Company |
UK, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067 · Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
|
Phase 3 |
Active, closed |
National Cancer Institute (NCI) |
Mexico |
|
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
|
Phase 3 |
Active, closed |
Astellas Pharma Global Development, Inc |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel |
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea |
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
NCT04547504 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer
|
Phase 3 |
Active, closed |
University Hospital, Brest |
France |
|
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel |
|
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Israel |
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594 · ClinicalTrials.gov ↗ · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma
|
Phase 3 |
Active, closed |
Alliance for Clinical Trials in Oncology |
Mexico |
|
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
|
Phase 3 |
Active, closed |
Pfizer |
UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Israel |
|
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel |
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
AstraZeneca |
USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan |
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Italy, Netherlands, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel |
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254 · Metastatic Melanoma, Unresectable Melanoma
|
Phase 3 |
Active, closed |
IO Biotech |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Australia, Israel |
|
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
|
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
|
Phase 3 |
Active, closed |
Daiichi Sankyo |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
China |
|
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
|
Phase 3 |
Active, closed |
Regeneron Pharmaceuticals |
Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Australia |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286 · Triple Negative Breast Cancer, PD-L1 Positive
|
Phase 3 |
Active, closed |
Gilead Sciences |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
AK112 in Advanced Non-Small Cell Lung Cancer
NCT05499390 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer
|
Phase 3 |
Active, closed |
Akeso |
China |
|
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Gilead Sciences |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel |
|
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
|
Phase 3 |
Active, closed |
Daiichi Sankyo |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
|
Phase 3 |
Active, closed |
Regeneron Pharmaceuticals |
Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Australia, Israel |
|
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
|
Phase 3 |
Active, closed |
AstraZeneca |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Canada, Brazil, Japan, South Korea, Taiwan |
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
SWOG Cancer Research Network |
Mexico, Israel |
|
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
|
Phase 3 |
Active, closed |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan |
|
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
USA, China, France, Spain, Poland, Turkey, Brazil, Japan, Taiwan |
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
China |
|
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
|
Phase 3 |
Active, closed |
Summit Therapeutics |
Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Turkey, Canada, Mexico, Japan |
|
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
|
Phase 3 |
Active, closed |
Seagen, a wholly owned subsidiary of Pfizer |
Ireland, UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Czechia, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
|
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
|
Phase 3 |
Active, closed |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Ireland, USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
|
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
|
Phase 3 |
Active, closed |
AstraZeneca |
UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia |
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574 · Lung Cancer, Non-squamous, Non-small Cell
|
Phase 3 |
Active, closed |
Boehringer Ingelheim |
UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Norway, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
NCT06212752 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
Japan |
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721 · Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Amgen |
UK, USA, Germany, France, Spain, Italy, Poland, Austria, Turkey, Brazil, Japan, South Korea, Taiwan, Israel |
|
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Samsung Bioepis Co., Ltd |
India, Germany, Spain, Turkey, Brazil, Mexico, Japan |
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866 · ClinicalTrials.gov ↗ · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 |
Active, closed |
Amgen |
Germany, France, Spain, Italy, Poland, Turkey, Mexico, South Korea, Taiwan |
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd |
China |
|
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
|
Phase 3 |
Active, closed |
GlaxoSmithKline |
USA, India, China, Germany, France, Spain, Netherlands, Belgium, Sweden, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan |
|
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
|
Phase 3 |
Active, closed |
Genmab |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
|
Phase 3 |
Active, closed |
NovoCure GmbH |
UK, USA, Germany, France, Spain, Italy, Poland, Switzerland, Czechia, Canada, Japan, Israel |
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
|
Phase 3 |
Active, closed |
Alliance for Clinical Trials in Oncology |
Mexico |
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
|
Phase 3 |
Active, closed |
Genmab |
Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
|
Phase 3 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, Spain, Poland, Turkey, Japan, South Korea |
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 3 |
Active, closed |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd |
China |
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 |
Active, closed |
Immutep S.A.S |
Ireland, UK, USA, India, Germany, Spain, Italy, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Australia |
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
|
Phase 3 |
Active, closed |
Qilu Pharmaceutical Co., Ltd |
India, China, Spain, Poland, Turkey, Israel |
|
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
|
Phase 2/3 |
Active, closed |
Canadian Cancer Trials Group |
Canada |
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205 · Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
|
Phase 2/3 |
Active, closed |
BioNTech SE |
UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Australia, Israel |
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05096663 · ClinicalTrials.gov ↗ · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
|
Phase 2/3 |
Active, closed |
SWOG Cancer Research Network |
Mexico, Egypt |
|
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
Phase 2/3 |
Active, closed |
IDEAYA Biosciences |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Canada, Australia, Israel |
|
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2/3 |
Active, closed |
Exelixis |
UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia, Israel |
|
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2/3 |
Active, closed |
AbbVie |
USA, France, Spain, Netherlands, Belgium, Turkey, Japan, Taiwan, Australia, Israel |
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2/3 |
Active, closed |
TJ Biopharma Co., Ltd |
China |
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
NCT02644369 · ClinicalTrials.gov ↗ · Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer
|
Phase 2 |
Active, closed |
University Health Network, Toronto |
Canada |
|
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
|
Phase 2 |
Active, closed |
Melanoma Institute Australia |
Australia |
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02965716 · Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Egypt |
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT03029403 · ClinicalTrials.gov ↗ · Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma
|
Phase 2 |
Active, closed |
University Health Network, Toronto |
Canada |
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
NCT03092323 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma of the Extremity
|
Phase 2 |
Active, closed |
Sarcoma Alliance for Research through Collaboration |
Italy, Canada, Australia |
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771 · ClinicalTrials.gov ↗ · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
|
Phase 2 |
Active, closed |
NRG Oncology |
Canada, Mexico, Israel |
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
NCT03149029 · ClinicalTrials.gov ↗ · Metastatic Melanoma
|
Phase 2 |
Active, closed |
Massachusetts General Hospital |
Israel |
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma
|
Phase 2 |
Active, closed |
ImmunityBio, Inc |
USA |
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
NCT03313206 · ClinicalTrials.gov ↗ · Head and Neck Mucosal Melanomas
|
Phase 2 |
Active, closed |
Gustave Roussy, Cancer Campus, Grand Paris |
France |
|
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Brazil, Mexico, South Korea |
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer
|
Phase 2 |
Active, closed |
Seagen, a wholly owned subsidiary of Pfizer |
UK, USA, Germany, France, Spain, Italy, Canada |
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer
|
Phase 2 |
Active, closed |
Astellas Pharma Global Development, Inc |
USA, France, Italy, Japan, South Korea, Taiwan |
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
NCT03515798 · ClinicalTrials.gov ↗ · Inflammatory Breast Cancer
|
Phase 2 |
Active, closed |
Institut Paoli-Calmettes |
France |
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279 · ClinicalTrials.gov ↗ · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
|
Phase 2 |
Active, closed |
ECOG-ACRIN Cancer Research Group |
Egypt |
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 |
Active, closed |
RTOG Foundation, Inc |
Canada |
|
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
|
Phase 2 |
Active, closed |
Gilead Sciences |
UK, USA, Germany, France, Spain, Italy, Turkey, Mexico, South Korea |
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019 · Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
|
Phase 2 |
Active, closed |
National Cancer Institute (NCI) |
Mexico |
|
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
|
Phase 2 |
Active, closed |
Chinese University of Hong Kong |
Singapore |
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
NCT03747120 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer
|
Phase 2 |
Active, closed |
University of Texas Southwestern Medical Center |
Mexico |
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352 · Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
|
Phase 2 |
Active, closed |
ImmunoVaccine Technologies, Inc. (IMV Inc.) |
USA, Canada |
|
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
|
Phase 2 |
Active, closed |
ModernaTX, Inc |
USA, Australia |
Pembrolizumab for Newly Diagnosed Glioblastoma
NCT03899857 · ClinicalTrials.gov ↗ · Newly Diagnosed Glioblastoma
|
Phase 2 |
Active, closed |
University of Zurich |
Switzerland |
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
NCT03989089 · ClinicalTrials.gov ↗ · HER2-Negative Breast Cancer
|
Phase 2 |
Active, closed |
University of Malaya |
Singapore |
|
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
|
Phase 2 |
Active, closed |
CHU de Quebec-Universite Laval |
Canada |
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
NCT04040361 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
|
Phase 2 |
Active, closed |
National Cancer Center Hospital East |
Japan |
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
NCT04074096 · ClinicalTrials.gov ↗ · Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
|
Phase 2 |
Active, closed |
UNICANCER |
France |
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
NCT04207086 · ClinicalTrials.gov ↗ · Melanoma Stage III
|
Phase 2 |
Active, closed |
Melanoma Institute Australia |
Australia |
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT04225117 · Locally Advanced or Metastatic Malignant Solid Tumors
|
Phase 2 |
Active, closed |
Astellas Pharma Global Development, Inc |
USA, Canada, Japan |
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
NCT04287829 · ClinicalTrials.gov ↗ · Mesotheliomas Pleural
|
Phase 2 |
Active, closed |
The Netherlands Cancer Institute |
Netherlands |
|
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
|
Phase 2 |
Active, closed |
AstraZeneca |
UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan |
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
NCT04417166 · ClinicalTrials.gov ↗ · Lymphoma, Extranodal NK-T-Cell
|
Phase 2 |
Active, closed |
International Extranodal Lymphoma Study Group (IELSG) |
China |
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699 · ClinicalTrials.gov ↗ · Vulvar Cancer, Vulvar Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
Massachusetts General Hospital |
Israel |
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
|
Phase 2 |
Active, closed |
Seagen, a wholly owned subsidiary of Pfizer |
USA, Mexico, Japan |
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406 · ClinicalTrials.gov ↗ · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
|
Phase 2 |
Active, closed |
ECOG-ACRIN Cancer Research Group |
Mexico |
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
NCT04575961 · ClinicalTrials.gov ↗ · Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma
|
Phase 2 |
Active, closed |
North Eastern German Society of Gynaecological Oncology |
Germany |
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
NCT04675294 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
ALX Oncology Inc |
UK, USA, Spain, Netherlands, Belgium, Canada, South Korea, Singapore, Australia |
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
NCT04675333 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
ALX Oncology Inc |
UK, USA, Spain, Netherlands, Belgium, South Korea, Singapore, Australia |
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514 · ClinicalTrials.gov ↗ · Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
|
Phase 2 |
Active, closed |
ARCAGY/ GINECO GROUP |
Germany, France, Belgium |
|
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
|
Phase 2 |
Active, closed |
National Cancer Center Hospital East |
Japan |
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
NCT04795661 · ClinicalTrials.gov ↗ · Localized Resectable Tumor, MSI/dMMR
|
Phase 2 |
Active, closed |
Centre Leon Berard |
France |
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
NCT04825990 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
|
Phase 2 |
Active, closed |
Gruppo Oncologico del Nord-Ovest |
Italy |
|
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Turkey, Canada, South Korea |
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634 · ClinicalTrials.gov ↗ · Neoplasm Malignant
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
USA, France, Spain, Netherlands, Belgium, South Korea, Australia, Israel |
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
NCT05033756 · ClinicalTrials.gov ↗ · Malignant Neoplasm of Breast, Breast Cancer
|
Phase 2 |
Active, closed |
Institut fuer Frauengesundheit |
Germany |
|
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
|
Phase 2 |
Active, closed |
Shanghai Chest Hospital |
China |
|
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
|
Phase 2 |
Active, closed |
Cambridge University Hospitals NHS Foundation Trust |
Australia |
|
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
|
Phase 2 |
Active, closed |
The Netherlands Cancer Institute |
Netherlands |
|
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
|
Phase 2 |
Active, closed |
Gilead Sciences |
UK, USA, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia |
|
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
|
Phase 2 |
Active, closed |
Pfizer |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Norway, Canada, Australia |
|
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
Hokkaido University Hospital |
Japan |
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
NCT05286437 · ClinicalTrials.gov ↗ · Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
|
Phase 2 |
Active, closed |
National Cancer Centre, Singapore |
Singapore |
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573 · Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
|
Phase 2 |
Active, closed |
Fujifilm Pharmaceuticals U.S.A., Inc |
USA |
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
|
Phase 2 |
Active, closed |
Peking Union Medical College Hospital |
China |
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
NCT05384015 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage
|
Phase 2 |
Active, closed |
Fundación GECP |
Spain |
Pembrolizumab in Muscle-invasive Bladder Cancer
NCT05406713 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma
|
Phase 2 |
Active, closed |
Matthew Galsky |
Mexico |
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
NCT05433116 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
Universität des Saarlandes |
Germany |
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298 · ClinicalTrials.gov ↗ · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma
|
Phase 2 |
Active, closed |
OncoC4, Inc |
USA, Egypt |
Surgical Pembro +/- Olaparib w TMZ for rGBM
NCT05463848 · ClinicalTrials.gov ↗ · Glioblastoma, Recurrent Glioblastoma
|
Phase 2 |
Active, closed |
L. Nicolas Gonzalez Castro, MD, PhD |
Israel |
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
NCT05563467 · ClinicalTrials.gov ↗ · Adrenocortical Carcinoma
|
Phase 2 |
Active, closed |
Maria Sklodowska-Curie National Research Institute of Oncology |
Poland |
|
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
|
Phase 2 |
Active, closed |
GlaxoSmithKline |
UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea |
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
NCT05578664 · ClinicalTrials.gov ↗ · Oligometastatic Renal Cell Carcinoma
|
Phase 2 |
Active, closed |
Consorzio Oncotech |
Italy |
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
NCT05585814 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer
|
Phase 2 |
Active, closed |
Shanghai Changzheng Hospital |
China |
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
NCT05599789 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic
|
Phase 2 |
Active, closed |
Peking Union Medical College Hospital |
China |
|
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
|
Phase 2 |
Active, closed |
Klus Pharma Inc |
USA, China, Belgium, Poland, Canada, Australia |
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
NCT05737199 · ClinicalTrials.gov ↗ · Ovarian Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
Niigata University Medical & Dental Hospital |
Japan |
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC
|
Phase 2 |
Active, closed |
Shanghai Chest Hospital |
China |
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
|
Phase 2 |
Active, closed |
Klus Pharma Inc |
China, Spain, Turkey, South Korea |
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
NCT05894889 · ClinicalTrials.gov ↗ · Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
|
Phase 2 |
Active, closed |
Peking University |
China |
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer
|
Phase 2 |
Active, closed |
Taiho Oncology, Inc |
USA, Germany, France, Spain |
|
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
|
Phase 2 |
Active, closed |
AstraZeneca |
USA |
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
NCT06041802 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
Japan |
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782 · Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
USA, France, Poland, Turkey, Japan, Australia |
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
NCT06180733 · ClinicalTrials.gov ↗ · Endometrial Cancer
|
Phase 2 |
Active, closed |
University Medical Center Groningen |
Netherlands |
|
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
|
Phase 2 |
Active, closed |
BicycleTx Limited |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
|
Phase 2 |
Active, closed |
Eikon Therapeutics |
USA |
|
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, South Korea, Taiwan, Australia, Israel |
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
NCT06318286 · ClinicalTrials.gov ↗ · Malignant Pleural Mesothelioma
|
Phase 2 |
Active, closed |
Hyogo Medical University |
Japan |
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394 · Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, Spain, Poland, Turkey, Mexico, South Korea, Australia |
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
NCT06557889 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck
|
Phase 2 |
Active, closed |
Institut Claudius Regaud |
France |
|
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
|
Phase 2 |
Active, closed |
CytoDyn, Inc |
USA |
|
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
|
Phase 2 |
Active, closed |
Merck Sharp & Dohme LLC |
USA, Spain, Italy, Poland, Turkey |
|
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
|
Phase 2 |
Active, closed |
Innovent Biologics (Suzhou) Co. Ltd |
China |
|
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
|
Phase 2 |
Active, closed |
Grupo Español Multidisciplinar de Melanoma |
Spain |
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
NCT07376317 · ClinicalTrials.gov ↗ · Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma
|
Phase 2 |
Active, closed |
Instituto do Cancer do Estado de São Paulo |
Brazil |
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
NCT03126630 · ClinicalTrials.gov ↗ · Pleural Malignant Mesothelioma
|
Phase 1/2 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
|
Phase 1/2 |
Active, closed |
Precision Biologics, Inc |
USA |
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868 · Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma
|
Phase 1/2 |
Active, closed |
Ascentage Pharma Group Inc |
USA, Australia |
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
NCT03647163 · Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma
|
Phase 1/2 |
Active, closed |
Vyriad, Inc |
USA |
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249 · Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
|
Phase 1/2 |
Active, closed |
Mirati Therapeutics Inc |
USA |
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
NCT03813394 · Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
|
Phase 1/2 |
Active, closed |
National University Hospital, Singapore |
Singapore |
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
NCT03854474 · ClinicalTrials.gov ↗ · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
|
Phase 1/2 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
NCT03970746 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 1/2 |
Active, closed |
PDC*line Pharma SAS |
Germany, France, Netherlands, Belgium, Poland |
|
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
|
Phase 1/2 |
Active, closed |
Nouscom SRL |
UK, USA, Spain, Italy, Belgium, Canada |
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
|
Phase 1/2 |
Active, closed |
Genmab |
UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel |
|
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
|
Phase 1/2 |
Active, closed |
TME Pharma AG |
Germany |
|
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
|
Phase 1/2 |
Active, closed |
Linnaeus Therapeutics, Inc |
USA, Mexico |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526 · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma
|
Phase 1/2 |
Active, closed |
OncoC4, Inc |
USA, Australia |
|
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
|
Phase 1/2 |
Active, closed |
Geneos Therapeutics |
USA |
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
NCT04305795 · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1/2 |
Active, closed |
Rakuten Medical, Inc |
USA |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362 · Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms
|
Phase 1/2 |
Active, closed |
BicycleTx Limited |
UK, USA, France, Spain, Italy, Canada |
|
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
|
Phase 1/2 |
Active, closed |
Mural Oncology, Inc |
USA, Spain |
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640 · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms
|
Phase 1/2 |
Active, closed |
Eli Lilly and Company |
USA, France, Canada, Japan, South Korea, Australia |
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
NCT05053880 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Multiforme(GBM)
|
Phase 1/2 |
Active, closed |
Accendatech USA Inc |
USA |
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609 · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
|
Phase 1/2 |
Active, closed |
Ascendis Pharma Oncology Division A/S |
USA, Spain, Italy, Belgium, Poland, Canada, South Korea, Taiwan, Singapore, Australia |
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
|
Phase 1/2 |
Active, closed |
Medicenna Therapeutics, Inc |
Ireland, USA, Spain, Switzerland, Portugal, Canada, South Korea, Australia |
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487 · Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Phase 1/2 |
Active, closed |
Nimbus Saturn, Inc |
USA |
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318 · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
|
Phase 1/2 |
Active, closed |
TILT Biotherapeutics Ltd |
USA |
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420 · Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer
|
Phase 1/2 |
Active, closed |
Qurient Co., Ltd |
USA, South Korea |
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320 · Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)
|
Phase 1/2 |
Active, closed |
Immuneering Corporation |
USA |
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814 · Metastatic Urothelial Carcinoma, Urothelial Neoplasms
|
Phase 1/2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, France, Spain, Italy, Netherlands, Canada, South Korea, Taiwan, Australia, Israel |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492 · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer
|
Phase 1/2 |
Active, closed |
Tango Therapeutics, Inc |
USA |
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136 · MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
|
Phase 1/2 |
Active, closed |
Servier Bio-Innovation LLC |
UK, USA, China, France, Spain, Italy, Belgium, Denmark, Austria, Canada, Brazil, Japan, Australia |
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
NCT06157541 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme, Astrocytoma, Grade IV
|
Phase 1/2 |
Active, closed |
Queensland Institute of Medical Research |
Australia |
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706 · ClinicalTrials.gov ↗ · Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
|
Phase 1/2 |
Active, closed |
BioInvent International AB |
Germany, Spain, Sweden, Denmark |
|
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
|
Phase 1/2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, Germany, France, Spain, Italy, Sweden, Poland, Turkey, Canada, South Korea, Australia |
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
|
Phase 1/2 |
Active, closed |
Merck Sharp & Dohme LLC |
UK, USA, France, Spain, Italy, Netherlands, Canada, South Korea, Taiwan, Israel |
|
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
|
Phase 1/2 |
Active, closed |
Daiichi Sankyo |
USA, China, Brazil, Japan |
|
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
|
Phase 1/2 |
Active, closed |
FBD Biologics Limited |
China |
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT06784648 · Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated
|
Phase 1/2 |
Active, closed |
BioInvent International AB |
UK, Germany, Spain |
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
NCT02298959 · ClinicalTrials.gov ↗ · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm
|
Phase 1 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565 · ClinicalTrials.gov ↗ · Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma
|
Phase 1 |
Active, closed |
National Cancer Institute (NCI) |
Canada |
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751 · Non Small Cell Lung Cancer, Breast Cancer
|
Phase 1 |
Active, closed |
Eli Lilly and Company |
USA, France, Spain, Italy, Belgium, Turkey, Taiwan |
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
NCT03030378 · ClinicalTrials.gov ↗ · Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
|
Phase 1 |
Active, closed |
National Cancer Institute (NCI) |
Israel |
|
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
|
Phase 1 |
Active, closed |
Syntrix Biosystems, Inc |
USA |
|
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
|
Phase 1 |
Active, closed |
ModernaTX, Inc |
UK, USA, Japan, Australia |
|
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
|
Phase 1 |
Active, closed |
Amgen |
UK, USA, Germany, France, Spain, Netherlands, Poland, Switzerland, Austria, Japan, Taiwan, Australia |
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03362060 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Metastatic Breast Cancer
|
Phase 1 |
Active, closed |
Massachusetts General Hospital |
Israel |
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397 · ClinicalTrials.gov ↗ · Selected Advanced Solid Tumors
|
Phase 1 |
Active, closed |
MedImmune LLC |
USA, France, Spain, Italy, Netherlands, Portugal, South Korea, Taiwan, Australia |
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
NCT03546426 · ClinicalTrials.gov ↗ · Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer
|
Phase 1 |
Active, closed |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
Italy |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339 · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour
|
Phase 1 |
Active, closed |
Nanobiotix |
USA |
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT03991819 · ClinicalTrials.gov ↗ · Non-small Cell Carcinoma
|
Phase 1 |
Active, closed |
University Health Network, Toronto |
Canada |
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701 · Breast Cancer, Non-small Cell Lung Carcinoma
|
Phase 1 |
Active, closed |
Daiichi Sankyo |
UK, USA, France, Spain |
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
NCT04046133 · ClinicalTrials.gov ↗ · Anal Cancer Stage III A, Anal Cancer Stage III B
|
Phase 1 |
Active, closed |
Cardiff University |
Norway |
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
|
Phase 1 |
Active, closed |
Amgen |
UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Austria, Canada, Japan, South Korea, Taiwan, Australia |
|
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
|
Phase 1 |
Active, closed |
Tizona Therapeutics, Inc |
USA |
|
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
|
Phase 1 |
Active, closed |
Daiichi Sankyo |
USA, Spain, Italy, Japan, Taiwan |
|
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
|
Phase 1 |
Active, closed |
Boehringer Ingelheim |
USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel |
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma
|
Phase 1 |
Active, closed |
Merck Sharp & Dohme LLC |
China |
|
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
|
Phase 1 |
Active, closed |
Cullinan Therapeutics Inc |
USA, Spain, Poland, Australia |
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
NCT05359445 · ClinicalTrials.gov ↗ · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
|
Phase 1 |
Active, closed |
Immatics Biotechnologies GmbH |
Germany |
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425 · Cancer, Tumor, Solid, Advanced Solid Tumor
|
Phase 1 |
Active, closed |
Nectin Therapeutics Ltd |
USA, Poland, Israel |
|
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
|
Phase 1 |
Active, closed |
Bayer |
UK, USA, China, France, Spain, Belgium, Canada, Singapore |
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929 · Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell
|
Phase 1 |
Active, closed |
Novartis Pharmaceuticals |
USA, China, Germany, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Singapore |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC
|
Phase 1 |
Active, closed |
Genentech, Inc |
USA, Spain, Netherlands, Belgium, Canada, South Korea, Taiwan, Australia |
|
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
|
Phase 1 |
Active, closed |
Bayer |
UK, USA, China, Spain, Belgium, Japan, South Korea |
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882 · Solid Tumor, Non Small Cell Lung Cancer, Melanoma
|
Phase 1 |
Active, closed |
Asher Biotherapeutics, Inc |
USA |
|
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
|
Phase 1 |
Active, closed |
DEKA Biosciences |
USA |
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587 · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer
|
Phase 1 |
Active, closed |
IDEAYA Biosciences |
USA |
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768 · MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
|
Phase 1 |
Active, closed |
Novartis Pharmaceuticals |
UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Norway, Japan, South Korea, Taiwan, Singapore, Israel |
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT05853367 · Metastatic Solid Tumors, Advanced Solid Tumors
|
Phase 1 |
Active, closed |
Merck Sharp & Dohme LLC |
USA, Spain, Poland, Switzerland, Canada, Israel |
|
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
|
Phase 1 |
Active, closed |
Glenmark Specialty S.A |
USA, India |
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
NCT05929235 · Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
|
Phase 1 |
Active, closed |
Flare Therapeutics Inc |
USA |
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
NCT06049212 · Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1)
|
Phase 1 |
Active, closed |
Merck Sharp & Dohme LLC |
Japan |
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
NCT06057038 · ClinicalTrials.gov ↗ · Malignant Solid Tumor
|
Phase 1 |
Active, closed |
Genmab |
Japan |
|
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
|
Phase 1 |
Active, closed |
TILT Biotherapeutics Ltd |
USA |
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
NCT06268613 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
|
Phase 1 |
Active, closed |
Samsung Bioepis Co., Ltd |
Spain, Poland, Turkey, South Korea |
|
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
|
Phase 1 |
Active, closed |
D2M Biotherapeutics Inc |
USA, China |
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951 · Thoracic Tumors, Non-small Cell Lung Cancer
|
Phase 1 |
Active, closed |
Amgen |
USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia |
|
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
|
Phase 1 |
Active, closed |
Microbiotica Ltd |
UK, France, Spain, Italy |
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
|
Phase 1 |
Active, closed |
Eli Lilly and Company |
USA, Germany, France, Spain, Italy, Belgium, Japan, Taiwan |
|
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
|
Phase 1 |
Active, closed |
Boehringer Ingelheim |
UK, USA, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
|
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 |
Active, closed |
Byondis B.V |
UK, Spain, Belgium |
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335 · Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
|
Phase 1 |
Active, closed |
Shanghai Henlius Biotech |
USA, China, Turkey, Israel |
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
NCT07180862 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
|
Phase 1 |
Active, closed |
Bio-Thera Solutions |
China |
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
NCT03695952 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Biliary Tract Cancer
|
Observational |
Active, closed |
Asan Medical Center |
South Korea |
|
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
|
Observational |
Active, closed |
Bristol-Myers Squibb |
UK |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8
|
Not applicable |
Active, closed |
National Cancer Institute (NCI) |
Norway, Mexico, Israel |
|
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
|
Early Phase 1 |
Active, closed |
Presage Biosciences |
USA |
